SILVERARC CAPITAL MANAGEMENT, LLC
13F Reported Value
ⓘ$962.2M
incl. option notional
Equity Holdings
ⓘ$898.5M
Option Notional
ⓘ$63.6M
$25.7M puts / $37.9M calls
Holdings
73
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
SILVERARC CAPITAL MANAGEMENT, LLC disclosed 73 positions worth $962.2M in its Form 13F-HR for Q2 2026 — $898.5M in common stock plus $63.6M of put/call option positions (reported at underlying notional value, not premium at risk), led by $ASND (Ascendis Pharma A/S) at 6.1% of the equity portfolio, followed by $CELC and $COGT. During the quarter the fund opened 25 new positions and exited 25 — including a new stake in $ELVN. The portfolio is most concentrated in Healthcare (98.2% of disclosed assets). All figures are sourced directly from SILVERARC CAPITAL MANAGEMENT, LLC’s Form 13F-HR filing with the SEC under CIK 1816307.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 44.8#1,898
Quality
$55.0M206,234 sh - —
Quality
$52.4M500,996 sh - —
Quality
$49.6M1,280,707 sh - —
Quality
$47.9M1,301,979 sh - 25.3
Quality
$42.7M2,017,009 sh - 22.6
Quality
$38.0M390,000 sh - 33.9
Quality
$34.6M311,461 sh - —
Quality
$33.6M352,802 sh - 30.3
Quality
$26.8M1,108,295 sh - 33.8
Quality
$26.5M1,214,390 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Ascendis Pharma A/S$ASND | 44.8#1,898 | $55.0M | 206,234 |
 Celcuity Inc.$CELC | — | $52.4M | 500,996 |
 Cogent Biosciences, Inc.$COGT | — | $49.6M | 1,280,707 |
 UroGen Pharma Ltd.$URGN | — | $47.9M | 1,301,979 |
 Immunome Inc.$IMNM | 25.3 | $42.7M | 2,017,009 |
 Dianthus Therapeutics, Inc. /DE/$DNTH | 22.6 | $38.0M | 390,000 |
 RHYTHM PHARMACEUTICALS, INC.$RYTM | 33.9 | $34.6M | 311,461 |
 Oruka Therapeutics, Inc.$ORKA | — | $33.6M | 352,802 |
 Monte Rosa Therapeutics, Inc.$GLUE | 30.3 | $26.8M | 1,108,295 |
 Syndax Pharmaceuticals Inc$SNDX | 33.8 | $26.5M | 1,214,390 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of SILVERARC CAPITAL MANAGEMENT, LLC's 73 positions.
Showing top 10 of 73 holdings.
Sector Allocation
Healthcare
$882.1M
Other
$12.5M
Financials
$3.9M
Full Holdings — SILVERARC CAPITAL MANAGEMENT, LLC (Q2 2026)
All 73 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $ASND | Ascendis Pharma A/S | $55.0M | 6.1% | +65% | 44.8 |
| 2 | $CELC | Celcuity Inc. | $52.4M | 5.8% | +40% | — |
| 3 | $COGT | Cogent Biosciences, Inc. | $49.6M | 5.5% | -3% | — |
| 4 | $URGN | UroGen Pharma Ltd. | $47.9M | 5.3% | -13% | — |
| 5 | $IMNM | Immunome Inc. | $42.7M | 4.8% | +9% | 25.3 |
| 6 | $DNTH | Dianthus Therapeutics, Inc. /DE/ | $38.0M | 4.2% | -40% | 22.6 |
| 7 | $RYTM | RHYTHM PHARMACEUTICALS, INC. | $34.6M | 3.9% | +2% | 33.9 |
| 8 | $ORKA | Oruka Therapeutics, Inc. | $33.6M | 3.7% | +134% | — |
| 9 | $GLUE | Monte Rosa Therapeutics, Inc. | $26.8M | 3.0% | -45% | 30.3 |
| 10 | $SNDX | Syndax Pharmaceuticals Inc | $26.5M | 3.0% | +37% | 33.8 |
| 11 |  $ELVN | Enliven Therapeutics, Inc. | $24.8M | 2.8% | NEW | — |
| 12 |  $IMVT | Immunovant, Inc. | $23.9M | 2.6% | +49% | — |
| 13 |  $ERAS | Erasca, Inc. | $23.1M | 2.6% | -32% | — |
| 14 |  $SGMT | Sagimet Biosciences Inc. | $22.6M | 2.5% | NEW | — |
| 15 |  $ABVX | Abivax S.A. | $22.6M | 2.5% | -44% | — |
| 16 |  $PRAX | Praxis Precision Medicines, Inc. | $22.0M | 2.5% | -8% | — |
| 17 |  $KOD | Kodiak Sciences Inc. | $21.3M | 2.4% | -45% | — |
| 18 | — | ARK ETF TR - PUT | $21.0M | — | NEW | — |
| 19 |  $DFTX | Definium Therapeutics, Inc. | $18.8M | 2.1% | NEW | — |
| 20 |  $VCYT | VERACYTE, INC. | $18.7M | 2.1% | +77% | 68.6 |
| 21 | $SNDXCALL | Syndax Pharmaceuticals Inc | $15.2M | — | +117% | 33.8 |
| 22 |  $GH | Guardant Health, Inc. | $15.0M | 1.7% | +1% | 39 |
| 23 |  $CCCC | C4 Therapeutics, Inc. | $14.2M | 1.6% | +59% | 18.2 |
| 24 |  $ZBIO | Zenas BioPharma, Inc. | $12.9M | 1.4% | -55% | 7.4 |
| 25 |  $TRVI | Trevi Therapeutics, Inc. | $12.6M | 1.4% | +33% | — |
| 26 | — | HELIX ACQUISITION CORP III - USD CL A ORD SHS | $12.5M | 1.4% | -3% | — |
| 27 |  $ALXO | ALX ONCOLOGY HOLDINGS INC | $11.9M | 1.3% | NEW | — |
| 28 |  $MANE | Veradermics, Inc | $11.7M | 1.3% | NEW | — |
| 29 |  $XENE | Xenon Pharmaceuticals Inc. | $11.3M | 1.3% | -6% | 24 |
| 30 |  $AVLN | Avalyn Pharma Inc. | $10.9M | 1.2% | NEW | — |
| 31 |  $BIIB | BIOGEN INC. | $10.4M | 1.2% | -6% | 64.7 |
| 32 |  $ACRS | Aclaris Therapeutics, Inc. | $10.3M | 1.1% | NEW | 12 |
| 33 |  $CERS | CERUS CORP | $10.1M | 1.1% | +9% | 38.5 |
| 34 |  $AVTX | Avalo Therapeutics, Inc. | $9.2M | 1.0% | NEW | 11.7 |
| 35 |  $BNTC | Benitec Biopharma Inc. | $9.1M | 1.0% | -5% | — |
| 36 |  $PCVX | Vaxcyte, Inc. | $8.4M | 0.9% | +0% | — |
| 37 |  $WGS | GeneDx Holdings Corp. | $8.4M | 0.9% | NEW | 35.4 |
| 38 |  $SVRA | Savara Inc | $8.3M | 0.9% | -5% | — |
| 39 |  $OVID | Ovid Therapeutics Inc. | $8.3M | 0.9% | +210% | 26.4 |
| 40 |  $ORIC | Oric Pharmaceuticals, Inc. | $8.0M | 0.9% | -33% | — |
| 41 | $ORICCALL | Oric Pharmaceuticals, Inc. | $7.4M | — | NEW | — |
| 42 | $GLUECALL | Monte Rosa Therapeutics, Inc. | $7.3M | — | NEW | 30.3 |
| 43 |  $CMPS | COMPASS Pathways plc | $7.1M | 0.8% | +68% | — |
| 44 |  $CGEN | COMPUGEN LTD | $6.8M | 0.8% | -4% | — |
| 45 |  $SLDB | Solid Biosciences Inc. | $6.7M | 0.7% | NEW | — |
| 46 | $ABVXCALL | Abivax S.A. | $6.7M | — | NEW | — |
| 47 |  $IBIO | iBio, Inc. | $6.2M | 0.7% | +1458% | 10.4 |
| 48 |  $IRON | Disc Medicine, Inc. | $6.1M | 0.7% | -58% | — |
| 49 |  $ALKS | Alkermes plc. | $5.9M | 0.7% | -75% | — |
| 50 |  $SYRE | Spyre Therapeutics, Inc. | $5.3M | 0.6% | -68% | — |
| 51 |  $ARTV | Artiva Biotherapeutics, Inc. | $5.1M | 0.6% | NEW | 9.7 |
| 52 |  $CTNM | Contineum Therapeutics, Inc. | $4.9M | 0.5% | -2% | — |
| 53 |  $QURE | uniQure N.V. | $4.8M | 0.5% | NEW | — |
| 54 |  $RACC | Research Alliance Corp III | $3.9M | 0.4% | NEW | — |
| 55 |  $ABEO | ABEONA THERAPEUTICS INC. | $3.8M | 0.4% | -6% | 23.7 |
| 56 |  $INSM | INSMED Inc | $3.7M | 0.4% | -4% | 39.4 |
| 57 |  $KPTI | Karyopharm Therapeutics Inc. | $2.9M | 0.3% | NEW | 15.1 |
| 58 |  $KYMRPUT | Kymera Therapeutics, Inc. | $2.9M | — | NEW | 28.4 |
| 59 |  $CAMP | Camp4 Therapeutics Corp | $2.9M | 0.3% | +0% | 25.3 |
| 60 |  $ELUT | ELUTIA INC. | $2.1M | 0.2% | -12% | — |
| 61 |  $RVMD | Revolution Medicines, Inc. | $1.9M | 0.2% | NEW | — |
| 62 |  $SION | Sionna Therapeutics, Inc. | $1.9M | 0.2% | +8% | — |
| 63 |  $ABSIPUT | Absci Corp | $1.8M | — | NEW | 7 |
| 64 |  $TELA | TELA Bio, Inc. | $1.6M | 0.2% | -5% | 25.2 |
| 65 |  $ACHV | ACHIEVE LIFE SCIENCES, INC. | $1.5M | 0.2% | NEW | — |
| 66 |  $FULCCALL | Fulcrum Therapeutics, Inc. | $1.4M | — | +0% | 32.9 |
| 67 |  $GUTS | FRACTYL HEALTH, INC. | $1.3M | 0.1% | -4% | 10 |
| 68 |  $CNTB | Connect Biopharma Holdings Ltd | $1.3M | 0.1% | NEW | — |
| 69 |  $CBIO | CRESCENT BIOPHARMA, INC. | $1.1M | 0.1% | -55% | 9.6 |
| 70 |  $CLRB | Cellectar Biosciences, Inc. | $894,404 | 0.1% | NEW | — |
| 71 |  $FHTX | Foghorn Therapeutics Inc. | $224,358 | 0.0% | NEW | 16.1 |
| 72 |  $ADGM | Adagio Medical Holdings, Inc. | $146,193 | 0.0% | -11% | — |
| 73 |  $RCKT | ROCKET PHARMACEUTICALS, INC. | $356 | 0.0% | +0% | — |
New Positions (25)
$ELVN Enliven Therapeutics, Inc.$24.8M$SGMT Sagimet Biosciences Inc.$22.6M$DFTX Definium Therapeutics, Inc.$18.8M$ALXO ALX ONCOLOGY HOLDINGS INC$11.9M$MANE Veradermics, Inc$11.7M$AVLN Avalyn Pharma Inc.$10.9M$ACRS Aclaris Therapeutics, Inc.$10.3M$AVTX Avalo Therapeutics, Inc.$9.2M$WGS GeneDx Holdings Corp.$8.4M$ORICCALL Oric Pharmaceuticals, Inc.$7.4M$GLUECALL Monte Rosa Therapeutics, Inc.$7.3M$SLDB Solid Biosciences Inc.$6.7M$ABVXCALL Abivax S.A.$6.7M$ARTV Artiva Biotherapeutics, Inc.$5.1MExited Positions (25)
$KALV KalVista Pharmaceuticals, Inc.
$NUVL Nuvalent, Inc.
$CNTA Centessa Pharmaceuticals plc
$SRRK Scholar Rock Holding Corp
$CGON CG Oncology, Inc.$QURECALL uniQure N.V.$CELCCALL Celcuity Inc.
$CLDX Celldex Therapeutics, Inc.
$CYTK CYTOKINETICS INC
$CLYM Climb Bio, Inc.
$CMPX Compass Therapeutics, Inc.
$SRZN Surrozen, Inc./DE
$ZURA Zura Bio Ltd$FULC Fulcrum Therapeutics, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for SILVERARC CAPITAL MANAGEMENT, LLC including:
Track SILVERARC CAPITAL MANAGEMENT, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for SILVERARC CAPITAL MANAGEMENT, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: SILVERARC CAPITAL MANAGEMENT, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For SILVERARC CAPITAL MANAGEMENT, LLC (SEC CIK: 1816307), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in SILVERARC CAPITAL MANAGEMENT, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.